Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using vibration-controlled transient elastography: A systemic review and meta-analysis

Jung Hwan Yu, Ji Won Han, Young Ju Suh, Young Eun Chon, Hee Yeon Kim, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Dae Won Jun, Han Ah Lee, Mi Na Kim

Clin Mol Hepatol. 2024;30(Suppl):S186-S198. Published online August 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0366

View: 1043 Download: 71 Crossref: 1

Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis

Han Ah Lee, Mi Na Kim, Hye Ah Lee, Miyoung Choi, Jung Hwan Yu, Young-Joo Jin, Hee Yeon Kim, Ji Won Han, Seung Up Kim, Jihyun An, Young Eun Chon

Clin Mol Hepatol. 2024;30(Suppl):S172-S185. Published online August 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0262

View: 1372 Download: 112

Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis

Young-Joo Jin, Hee Yeon Kim, Young Ju Suh, Chae Hyeon Lee, Jung Hwan Yu, Mi Na Kim, Ji Won Han, Han Ah Lee, Jihyun An, Young Eun Chon, Dae Won Jun, Miyoung Choi, Seung Up Kim

Clin Mol Hepatol. 2024;30(Suppl):S159-S171. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0163

View: 1249 Download: 95

Reply to Correspondence

Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”

Beom Kyung Kim

Clin Mol Hepatol. 2024;30(4):1044-1046. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0584

View: 608 Download: 20

Reply to correspondence on “Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis”

Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):1042-1043. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0685

View: 615 Download: 26 Web of Science: 1 Crossref: 1

Reply to correspondence on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):1037-1038. Published online May 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0320

View: 1107 Download: 52

Correspondence

Correspondence to editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su

Clin Mol Hepatol. 2024;30(4):1016-1018. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0365

View: 967 Download: 31

Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”

Su Bin Lim, Hyo Jung Cho

Clin Mol Hepatol. 2024;30(4):1009-1011. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0368

View: 988 Download: 56 Crossref: 1

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(4):1005-1008. Published online May 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0394

View: 1133 Download: 55

Correspondence to editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”

Haeryoung Kim, Dong Ho Lee, Yoon Jung Hwang

Clin Mol Hepatol. 2024;30(4):992-993. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0624

View: 683 Download: 31 Crossref: 1

Letter to the Editor

Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li

Clin Mol Hepatol. 2024;30(4):965-969. Published online June 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0386

View: 1455 Download: 76

Original Article

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2024;30(4):807-823. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0333

View: 1959 Download: 251 Web of Science: 1 Crossref: 2

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B

Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim

Clin Mol Hepatol. 2024;30(4):793-806. Published online July 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0252

View: 1745 Download: 167 Web of Science: 1 Crossref: 1

UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL

Renyu Zhang, Can Li, Shuai Zhang, Lingmin Kong, Zekun Liu, Yixiao Guo, Ying Sun, Cong Zhang, Yule Yong, Jianjun Lv, Meng Lu, Man Liu, Dong Wu, Tianjiao Zhang, Haijiao Yang, Ding Wei, Zhinan Chen, Huijie Bian

Clin Mol Hepatol. 2024;30(4):771-792. Published online June 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0236

View: 1607 Download: 256

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

Clin Mol Hepatol. 2024;30(4):735-755. Published online May 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0058

View: 2102 Download: 243 Crossref: 2

Editorial

Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”

Paul Y. Kwo

Clin Mol Hepatol. 2024;30(4):714-717. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0425

View: 1056 Download: 43 Web of Science: 1 Crossref: 1

Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Junlong Dai, Jimmy Che-To Lai, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2024;30(4):698-701. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0327

View: 995 Download: 43 Crossref: 1

Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”

Joseph C. Ahn, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):689-691. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0348

View: 1013 Download: 25 Crossref: 1

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Naoshi Nishida

Clin Mol Hepatol. 2024;30(4):682-688. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0324

View: 1024 Download: 89 Crossref: 1

Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

Seren M. Gedallovich, Paul Y. Kwo

Clin Mol Hepatol. 2024;30(4):677-681. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0418

View: 1004 Download: 27

Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon

Clin Mol Hepatol. 2024;30(4):659-662. Published online July 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0516

View: 928 Download: 74

Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”

Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):653-655. Published online July 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0482

View: 1012 Download: 55

Original Article

Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy

Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Chi‐Ming Tai, Chih-Wen Lin, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Chi-Yi Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chung, Ming-Jong Bair, Ming-Lung Yu, T-COACH Study Group

Clin Mol Hepatol. 2024;30(3):468-486. Published online April 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0038

View: 3129 Download: 177 Web of Science: 3 Crossref: 2

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George

Clin Mol Hepatol. 2024;30(3):436-448. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109

View: 4182 Download: 273 Web of Science: 8 Crossref: 9

Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma

Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su

Clin Mol Hepatol. 2024;30(3):406-420. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0103

View: 3093 Download: 165 Web of Science: 4 Crossref: 4

Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma

Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim

Clin Mol Hepatol. 2024;30(3):360-374. Published online March 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0042

View: 4045 Download: 320 Web of Science: 3 Crossref: 3

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(3):345-359. Published online March 12, 2024

DOI: https://doi.org/10.3350/cmh.2023.0553

View: 3915 Download: 393 Web of Science: 3 Crossref: 4

Letter to the Editor

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 2654 Download: 137 Web of Science: 5 Crossref: 6

Editorial

Steatotic liver disease: Know your enemies

Lung-Yi Mak

Clin Mol Hepatol. 2024;30(2):171-173. Published online February 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0078

View: 2419 Download: 85 Web of Science: 1 Crossref: 2

Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma

Ji Eun Han, Hyo Jung Cho

Clin Mol Hepatol. 2024;30(2):160-163. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0141

View: 2453 Download: 62

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 5098	MAFLD: How is it different from NAFLD?
Viewed By 5072	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 4498	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4472	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4363	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 138	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search